Larimar Therapeutics Inc Cash Flow Conversion Efficiency
Larimar Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Larimar Therapeutics Inc (LRMR) has a cash flow conversion efficiency ratio of -0.346x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-44.03 Million) by net assets ($127.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Larimar Therapeutics Inc (2012–2025)
Cash flow conversion efficiency of Larimar Therapeutics Inc from 2012 to 2025. This chart illustrates how Larimar Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View LRMR live share price for real-time trading data and today's change.
Larimar Therapeutics Inc Cash Flow Conversion Ratio Explained
Larimar Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Larimar Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Larimar Therapeutics Inc ranked by their cash flow conversion efficiency. Also see market cap of Larimar Therapeutics Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen Wongtee International Enterprise Co Ltd
SHE:000056
|
-0.023x |
|
Solowin Holdings
NASDAQ:AXG
|
-0.002x |
|
Tongxing Environmental Protection
SHE:003027
|
0.056x |
|
Nivika Fastigheter AB Series B
ST:NIVI-B
|
0.003x |
|
Avjennings Ltd
AU:AVJ
|
0.025x |
|
ARYZTA UN.ADR 1/2 SF -02
F:YZAU
|
N/A |
|
Zhejiang Tuna Environmental Science & Technology Co Ltd
SHG:603177
|
0.068x |
|
Pecca Group Bhd
KLSE:5271
|
0.122x |
Annual Cash Flow Conversion Efficiency for Larimar Therapeutics Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Larimar Therapeutics Inc from 2012 to 2025. Review Larimar Therapeutics Inc free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $78.08 Million | $-113.20 Million | -1.450x | -252.00% |
| 2024-12-31 | $171.81 Million | $-70.76 Million | -0.412x | -0.59% |
| 2023-12-31 | $81.72 Million | $-33.46 Million | -0.409x | -64.71% |
| 2022-12-31 | $110.90 Million | $-27.57 Million | -0.249x | +61.97% |
| 2021-12-31 | $64.41 Million | $-42.10 Million | -0.654x | -38.94% |
| 2020-12-31 | $89.69 Million | $-42.20 Million | -0.470x | -101.44% |
| 2019-12-31 | $-694.00K | $-22.70 Million | 32.707x | +6025.11% |
| 2018-12-31 | $93.27 Million | $-51.49 Million | -0.552x | +1.39% |
| 2017-12-31 | $78.22 Million | $-43.78 Million | -0.560x | -31.10% |
| 2016-12-31 | $121.73 Million | $-51.98 Million | -0.427x | -21.25% |
| 2015-12-31 | $169.11 Million | $-59.55 Million | -0.352x | -30.24% |
| 2014-12-31 | $104.44 Million | $-28.24 Million | -0.270x | +36.52% |
| 2013-12-31 | $35.22 Million | $-15.00 Million | -0.426x | +74.75% |
| 2012-12-31 | $8.06 Million | $-13.59 Million | -1.687x | -- |
About Larimar Therapeutics Inc
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.